Re:Goldman Sachs questions whether curing patients is a sust...
by lmm on Saturday April 14, 2018 @03:17AM
(#16836296)
It's very hard to argue against a safety trial - of course if you duplicate safety trials then there will be occasional cases where you catch something that the original trial missed. But ultimately far more people have died or suffered because a medicine wasn't available yet than been killed or hurt by medicine being approved too early.
[ Parent
| on HN ]
There are no comments on this comment yet.